Navigation Links
Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT
Date:7/29/2008

2008 American College of Chest Physicians (ACCP) Guidelines Will Increase

Use of Trellis(R) Peripheral Infusion System

NORTHBROOK, Ill., July 29 /PRNewswire/ -- The American College of Chest Physicians (ACCP) has published new evidence-based clinical guidelines for physicians that for the first time suggest the use of pharmacomechanical thrombolysis for acute iliofemoral deep vein thrombosis (DVT) in conjunction with anticoagulation drug therapy. The new guidelines appear in the July supplement to the CHEST journal.

"This is a major change in the recommendations for the care of these patients with extensive DVT, and represents a major advance in treatment. Adopting an initial strategy of thrombus removal will improve the quality of life of these patients and potentially avoid recurrent DVT in the future," stated Anthony J. Comerota, MD, FACS, FACC, Director of the Jobst Vascular Center and Adjunct Professor of Surgery, University of Michigan.

"The recommendation to treat certain cases of acute DVT with pharmacomechanical thrombolysis adds an important tool to help treat the acute problem as well as to minimize the long-term disability of post-thrombotic syndrome (PTS) in patients," added Katharine L. Krol, MD, Director, Vascular Interventional Radiology, CorVasc MDs, Indianapolis, IN and recent past president of the Society of Interventional Radiology (SIR).

The new Venous Thromboembolic (VTE) Disease guidelines represent an evolution from the previous ACCP standard which recommended the use of anticoagulation drug therapy alone for the treatment of DVT. For complete information on the new ACCP VTE Guidelines, visit http://www.TheNewGuidelines.org.

While anticoagulation alone mitigates the risk of clot propagation and pulmonary embolism, it often fails to clear the blockage. This residual thrombus can lead to venous hypertension, valvular insufficiency, skin ulcerations and post-thrombotic syndrome.

"The publication of the new 2008 ACCP guidelines suggesting the use of pharmacomechanical thrombolysis clearly establishes a new standard for thrombolytic therapy. We believe the Trellis(R) Isolated Pharmacomechanical Thrombolysis method provides the best available combination of safety and efficacy," remarked Scott Cramer, President and CEO of Bacchus Vascular, Inc.

Isolated pharmacomechanical thrombolysis using the Trellis Peripheral Infusion System from Bacchus Vascular, Inc. to deliver thrombolytic directly into a desired treatment segment has proven to be a rapid, effective and safe method of treating patients with acute DVT. The Trellis device is the only DVT treatment system that isolates the thrombus and targets the thrombolytic treatment.

About Bacchus Vascular

Bacchus Vascular, Inc. is a privately held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis(R) Peripheral Infusion System and other products.

For more information, visit http://www.bacchusvascular.com.

For complete information on the new ACCP VTE Guidelines, visit: http://www.TheNewGuidelines.org.


'/>"/>
SOURCE Bacchus Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rochester Medical Announces Third Quarter 2008 Earnings Conference Call July 31, 2008
2. Medline Signs 3-Year Purchasing Agreement for Mouth Rinse From Chester Labs
3. Rochester Medical Announces Second Quarter 2008 Earnings Conference Call April 29, 2008
4. Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility
5. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
6. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
7. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
8. National ePrescribing Patient Safety Initiative Supports Senates Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety
9. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
10. Lilly Backs Federal Legislation to Inform the Public on Payments to Physicians
11. More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- NX Prenatal Inc., a US based molecular ... early warning of adverse pregnancy outcomes, announced today ... Dr. Thomas McElrath of Brigham & ... (SMFM) annual meeting held in Atlanta ... presentation reported initial positive top-line results regarding the ...
(Date:2/10/2016)... 2016  Allergan plc (NYSE: AGN ) a ... Saunders , Allergan,s CEO and President, will be featured ... at the RBC Capital Markets Healthcare Conference on Tuesday, ... New York Palace Hotel in New York, ... and can be accessed on Allergan,s Investor Relations web ...
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics ... Photonics West conference in San Francisco’s Moscone Center from February 16-18, 2016, and ... , These latest InGaAs PIN diode standard packages feature a TO-46 metal can ...
(Date:2/10/2016)... ... February 10, 2016 , ... Global Stem ... agreement with Singapore-based Global Stem Cells Network (GSCN) and its affiliate Global ... in the latest adipose and bone marrow therapies. , Through the new ...
Breaking Biology Technology:
(Date:2/3/2016)... DUBLIN , Feb. 3, 2016 /PRNewswire/ ... announced the addition of the "Emotion ... NLP, Machine Learning, and Others), Software Tools ... Application Areas, End Users,and Regions - Global ... offering. --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) ...
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
Breaking Biology News(10 mins):